Dennis Schmatz joins Scynexis

Will provide advice to US firm as it advances drug development programme

US drug discovery company Scynexis says Dennis Schmatz has joined the company as a strategic advisor. Schmatz, an anti-infectives specialist, will provide advice to Scynexis’ management team as the company advances its drug development programmes.

Scynexis president and chief executive Dr Yves Ribeill, said: ‘His contributions to Scynexis will be important as we aggressively pursue the development of our cyclophilin inhibitor technology platform and the discovery of global health therapeutics for neglected diseases.’

Schmatz was most recently interim president and chief executive of the Medicines for Malaria Venture, a non-profit foundation in Geneva, Switzerland created to discover anti-malarial drugs through public-private partnerships. Previously he was vice president of Merck Research Laboratories USA and head of the Tsukuba Research Institute of Banyu Research Laboratories in Japan.

‘It's an exciting time to be joining the Scynexis team as both their HCV compounds, SCY-635, and their partnered broad-spectrum antifungal compound, MK-3118, advance through clinical development,’ Schmatz said. ‘I see a promising future for Scynexis and am honoured to be a part of it.’

You may also like

Research & Development

Cypralis to acquire Scynexis assets

The deal includes a large portfolio of cyclophilin inhibitors
Sustainability

Scynexis extends sleeping sickness collaboration to 2012

Extends collaboration with the Drugs for Neglected Diseases initiative (DNDi)
Research & Development

From lab to launch: transforming pharmaceutical formulation development with GEA’s CFC Lab Coater

A new generation of continuous film coating technology is giving R&D teams the speed, precision and scalability they need to take products from the laboratory to commercial production without the traditional bottlenecks
Manufacturing

Bristol Myers Squibb licenses Lonza ADC linker-payload technology for undisclosed target

BMS has secured exclusive access to Lonza’s SYNtecan linker-payload platform, alongside GlycoConnect and HydraSpace technologies, to advance development of an antibody-drug conjugate against an undisclosed target
Drug Delivery

Neuland Laboratories to partner with LIR Life Sciences for transdermal GLP-1 development

The pair will work to advance LIR Life's novel cell-penetrating peptides for next-generation obesity therapies, looking to improve patient adherence and broaden access
Hi Tech Manufacturing

Hongene to support SiranBio siRNA candidate programme with CDMO services

The RNA specialist will support SiranBio's SA1211 programme, helping advance the siRNA candidate through its vertically integrated CDMO services to address the complex nature of the next-gen therapeutic
Research & Development

Reacta Healthcare announces expansion into Asia-Pacific and appoints Professor Gary Wing-Kin Wong to advisory board

Reacta Healthcare, a leading developer and manufacturer of pharmaceutical-grade oral food challenge (OFC) products for food allergy diagnostics, today announces the appointment of Professor Gary Wing-Kin Wong, internationally recognised paediatric allergy and respiratory disease expert and President-Elect of the World Allergy Organisation (WAO), to its Advisory Board, as the company accelerates new product development and expands its Asia-Pacific (APAC) footprint
Subscribe now